Zantac Statute of Limitations — State-by-State 2026 Analysis

How the Discovery Rule Applies to Zantac Claims

In pharmaceutical injury cases, the statute of limitations typically begins running not on the date of drug exposure but on the date the claimant discovered — or with reasonable diligence should have discovered — the connection between the pharmaceutical product and their injury. This is called the discovery rule, and it prevents the limitations period from running before a claimant could reasonably be expected to know they had a legal claim. For Zantac claimants, the discovery rule analysis centers on when a reasonable person would have known that Zantac (ranitidine) may have caused their cancer. Courts frequently find that the FDA's April 1, 2020 market withdrawal, which received extensive national media coverage, placed the public on constructive notice of the Zantac-NDMA-cancer connection. This makes April 2020 the most commonly cited starting point for the limitations period in Zantac cases.

Key States and Their Deadlines

Delaware: 2-year statute of limitations for personal injury (10 Del. C. § 8119). With April 2020 as the constructive notice date, the April 2022 deadline has passed for pre-2020 diagnoses. However, Delaware courts have shown receptivity to discovery rule arguments where claimants can demonstrate individualized delayed discovery. For diagnoses occurring after April 2022, the 2-year window runs from the diagnosis date. California: 2-year SOL (CCP § 335.1) with the discovery rule. Pre-April 2020 diagnoses with constructive notice in April 2020 had a deadline of April 2022. Diagnoses from April 2020 onward are governed by 2 years from the discovery date. Florida: 2-year SOL (Fla. Stat. § 95.11(3)(a)) for personal injury, with the discovery rule applicable to latent pharmaceutical injuries. Texas: 2-year SOL (Tex. Civ. Prac. & Rem. Code § 16.003) from the date of discovery. New York: 3-year SOL (CPLR § 214) from the date of discovery in toxic exposure cases — more favorable for Zantac claimants. Pennsylvania: 2-year SOL (42 Pa. C.S. § 5524) from discovery. Ohio: 2-year SOL (ORC § 2305.10) from discovery. New Jersey: 2-year SOL (N.J.S.A. 2A:14-2) from discovery.

Arguments for Delayed Discovery in 2026

Claimants filing in 2026 whose cancer diagnoses predate 2022 may still have viable claims if they can present compelling delayed discovery arguments. Relevant facts supporting delayed discovery include: the claimant was not following news coverage of the Zantac recall in April 2020 due to other serious health issues (including dealing with cancer treatment itself); the claimant's treating physicians did not advise them of the Zantac-cancer connection at the time of diagnosis; the claimant did not consult a pharmaceutical litigation attorney until recently; or the connection between the claimant's specific cancer type and Zantac NDMA was not publicly known or widely accepted in April 2020 (relevant for breast and prostate cancer claims where the science is more recent). Courts evaluate delayed discovery arguments on a case-by-case basis, and the strength of the argument depends heavily on the specific facts of each claimant's situation.

Act Promptly — Every Deadline Is Non-Negotiable

Statutes of limitations are absolute deadlines that courts enforce strictly. Unlike some procedural requirements that can be waived or extended, a missed statute of limitations permanently bars a claim — regardless of how meritorious it is, how serious the injury is, or how financially solvent the defendants are. If you used Zantac for a year or more and were diagnosed with a qualifying cancer, the single most important step you can take right now is to contact a pharmaceutical litigation attorney for a free consultation to evaluate whether your claim is timely and what steps need to be taken immediately to protect your rights. This consultation is free, requires no commitment, and may be the difference between preserving and permanently losing your legal rights.